{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T16:53:35Z","timestamp":1765040015753},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,6,11]],"date-time":"2005-06-11T00:00:00Z","timestamp":1118448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1007\/s00384-005-0739-0","type":"journal-article","created":{"date-parts":[[2005,6,10]],"date-time":"2005-06-10T06:46:52Z","timestamp":1118386012000},"page":"276-281","source":"Crossref","is-referenced-by-count":38,"title":["Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn\u2019s disease"],"prefix":"10.1007","volume":"21","author":[{"given":"Dario","family":"Sorrentino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Avellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo Alberto","family":"Beltrami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Pasqual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Zearo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,6,11]]},"reference":[{"key":"739_CR1","first-page":"1775","volume-title":"Yamada textbook of gastroenterology","author":"WF Stenson","year":"1999","unstructured":"Stenson WF (1999) Inflammatory bowel disease. In: Yamada T, Alpers DH, Laine L, Owyang C, Powell DW (eds) Yamada textbook of gastroenterology. Lippincott Williams and Wilkins, Philadelphia, PA, pp 1775\u20131839"},{"key":"739_CR2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1053\/gast.2002.35393","volume":"123","author":"MT Abreu","year":"2002","unstructured":"Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H (2002) Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn\u2019s disease. Gastroenterology 123:679\u2013688","journal-title":"Gastroenterology"},{"key":"739_CR3","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/ng1345","volume":"36","author":"M Stoll","year":"2004","unstructured":"Stoll M, Corneliussen B, Costello CM, Waetzig GH, Mellgard B, Koch WA, Rosenstiel P, Albrecht M, Croucher PJ, Seegert D, Nikolaus S, Hampe J, Lengauer T, Pierrou S, Foelsch UR, Mathew CG, Lagerstrom-Fermer M, Schreiber S (2004) Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 36:476\u2013480","journal-title":"Nat Genet"},{"key":"739_CR4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/gut.52.4.552","volume":"52","author":"E Louis","year":"2003","unstructured":"Louis E, Michel V, Hugot JP, Reenaers C, Fontaine F, Delforge M, El Yafi F, Colombel JF, Belaiche J (2003) Early development of stricturing or penetrating pattern in Crohn\u2019s disease is influenced by disease location, number of flares, and smoking but not by NOD2\/CARD15 genotype. Gut 52:552\u2013557","journal-title":"Gut"},{"key":"739_CR5","first-page":"371","volume":"63","author":"KP Geboes","year":"2000","unstructured":"Geboes KP, Cabooter L, Geboes K (2000) Contribution of morphology for the comprehension of mechanisms of fibrosis in inflammatory enterocolitis. Acta Gastro-Enterol Belg 63:371\u2013376","journal-title":"Acta Gastro-Enterol Belg"},{"key":"739_CR6","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/gast.2002.31072","volume":"122","author":"WJ Sandborn","year":"2002","unstructured":"Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Lofberg R, Modigliani R, Present DH, Rutgeerts P, Scholmerich J, Stange EF, Sutherland LR (2002) A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn\u2019s disease. Gastroenterology 122:512\u2013530","journal-title":"Gastroenterology"},{"key":"739_CR7","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/gut.31.3.325","volume":"31","author":"G Olaison","year":"1990","unstructured":"Olaison G, Sjodahl R, Tagesson C (1990) Glucocorticoid treatment in ileal Crohn\u2019s disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 31:325\u2013328","journal-title":"Gut"},{"key":"739_CR8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0016-5107(95)70101-X","volume":"42","author":"C Ramboer","year":"1995","unstructured":"Ramboer C, Verhamme M, Dhondt E, Huys S, Van Eygen K, Vermeire L (1995) Endoscopic treatment of stenosis in recurrent Crohn\u2019s disease with balloon dilation combined with local corticosteroid injection. Gastrointest Endosc 42:252\u2013255","journal-title":"Gastrointest Endosc"},{"key":"739_CR9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00054725-200401000-00009","volume":"10","author":"G Assche Van","year":"2004","unstructured":"Van Assche G, Geboes K, Rutgeerts P (2004) Medical therapy for Crohn\u2019s disease strictures. Inflamm Bowel Dis 10:55\u201360","journal-title":"Inflamm Bowel Dis"},{"key":"739_CR10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","volume":"109","author":"HM Dullemen van","year":"1995","unstructured":"van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J (1995) Treatment of Crohn\u2019s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129\u2013135","journal-title":"Gastroenterology"},{"key":"739_CR11","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group. N Engl J Med 337:1029\u20131035","journal-title":"N Engl J Med"},{"key":"739_CR12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0016-5085(99)70224-6","volume":"116","author":"FJ Baert","year":"1999","unstructured":"Baert FJ, D\u2019Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn\u2019s ileocolitis. Gastroenterology 116:22\u201328","journal-title":"Gastroenterology"},{"key":"739_CR13","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1097\/00054725-200402001-00009","volume":"10","author":"GH Waetzig","year":"2004","unstructured":"Waetzig GH, Schreiber S (2004) Mechanisms of infliximab: the reverse side of a drug effect. Inflamm Bowel Dis 10:S38\u2013S43","journal-title":"Inflamm Bowel Dis"},{"key":"739_CR14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"JF Colombel","year":"2004","unstructured":"Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ (2004) The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 126:19\u201331","journal-title":"Gastroenterology"},{"key":"739_CR15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","volume":"116","author":"G D\u2019Haens","year":"1999","unstructured":"D\u2019Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn\u2019s disease: a European multicenter trial. Gastroenterology 116:1029\u20131034","journal-title":"Gastroenterology"},{"key":"739_CR16","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1016\/S0002-9270(02)05259-0","volume":"97","author":"GR Lichtenstein","year":"2002","unstructured":"Lichtenstein GR, Olson A, Bao W, Travers S, Diamond RH (2002) Infliximab treatment does not result in an increased risk of intestinal strictures or obstruction in Crohn\u2019s disease patients: accent I study results. Am J Gastroenterol 97:S254","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 3","key":"739_CR17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1046\/j.0953-0673.2003.01727.x","volume":"18","author":"MR Keighley","year":"2003","unstructured":"Keighley MR, Stockbrugger RW (2003) Inflammatory bowel disease. Aliment Pharmacol Ther 18(Suppl 3):66\u201370","journal-title":"Aliment Pharmacol Ther"},{"key":"739_CR18","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1136\/gut.33.7.938","volume":"33","author":"V Gumaste","year":"1992","unstructured":"Gumaste V, Sachar DB, Greenstein AJ (1992) Benign and malignant colorectal strictures in ulcerative colitis. Gut 33:938\u2013941","journal-title":"Gut"},{"key":"739_CR19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0016-5085(88)90411-8","volume":"94","author":"MF Graham","year":"1988","unstructured":"Graham MF, Diegelmann RF, Elson CO, Lindblad WJ, Gotschalk N, Gay S, Gay R (1988) Collagen content and types in the intestinal strictures of Crohn\u2019s disease. Gastroenterology 94:257\u2013265","journal-title":"Gastroenterology"},{"key":"739_CR20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF00916587","volume":"17","author":"MW Owens","year":"1993","unstructured":"Owens MW, Grisham MB (1993) Cytokines increase proliferation of human intestinal smooth muscle cells: possible role in inflammation-induced stricture formation. Inflammation 17:481\u2013487","journal-title":"Inflammation"},{"key":"739_CR21","first-page":"G653","volume":"279","author":"JB Pucilowska","year":"2000","unstructured":"Pucilowska JB, Williams KL, Lund PK (2000) Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol 279:G653\u2013G659","journal-title":"Am J Physiol"},{"key":"739_CR22","first-page":"G875","volume":"273","author":"EM Zimmermann","year":"1997","unstructured":"Zimmermann EM, Li L, Hou YT, Cannon M, Christman GM, Bitar KN (1997) IGF-I induces collagen and IGFBP-5 mRNA in rat intestinal smooth muscle. Am J Physiol 273:G875\u2013G882","journal-title":"Am J Physiol"},{"key":"739_CR23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0950-3528(96)90045-7","volume":"10","author":"G Radford-Smith","year":"1996","unstructured":"Radford-Smith G, Jewell DP (1996) Cytokines and inflammatory bowel disease. Bailli\u00e8re\u2019s Clin Gastroenterol 10:151\u2013164","journal-title":"Bailli\u00e8re\u2019s Clin Gastroenterol"},{"key":"739_CR24","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1053\/gast.2001.29035","volume":"121","author":"SJ Deventer van","year":"2001","unstructured":"van Deventer SJ (2001) Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn\u2019s disease. Gastroenterology 121:1242\u20131246","journal-title":"Gastroenterology"},{"key":"739_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s003840100285","volume":"16","author":"S Schreiber","year":"2001","unstructured":"Schreiber S, Campieri M, Colombel JF, van Deventer SJ, Feagan B, Fedorak R, Forbes A, Gassull M, Gendre JP, van Hogezand RA, Lofberg R, Modigliani R, Pallone F, Petritsch W, Prantera C, Rampton D, Seibold F, Vatn M, Zeitz M, Rutgeerts P (2001) BMBF competence network \u201cInflammatory Bowel disease\u201d. Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001\u20132003. Int J Colorectal Dis 16:1\u201311","journal-title":"Int J Colorectal Dis"},{"key":"739_CR26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","volume":"117","author":"P Rutgeerts","year":"1999","unstructured":"Rutgeerts P, D\u2019Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease. Gastroenterology 117:761\u2013769","journal-title":"Gastroenterology"},{"key":"739_CR27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2036.17.s2.20.x","volume":"17","author":"L Biancone","year":"2003","unstructured":"Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, Pallone F (2003) Review article: maintenance treatment of Crohn\u2019s disease. Aliment Pharmacol Ther 17:31\u201337","journal-title":"Aliment Pharmacol Ther"},{"key":"739_CR28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","volume":"126","author":"P Rutgeerts","year":"2004","unstructured":"Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease. Gastroenterology 126:402\u2013413","journal-title":"Gastroenterology"},{"key":"739_CR29","first-page":"193","volume":"64","author":"GV Assche","year":"2001","unstructured":"Assche GV (2001) Can we influence fibrosis in Crohn\u2019s disease? Acta Gastro-Enterol Belg 64:193\u2013196","journal-title":"Acta Gastro-Enterol Belg"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-005-0739-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00384-005-0739-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-005-0739-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:05:23Z","timestamp":1559059523000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00384-005-0739-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,11]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1007\/s00384-005-0739-0","relation":{},"ISSN":["0179-1958","1432-1262"],"issn-type":[{"value":"0179-1958","type":"print"},{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,11]]}}}